@inbook{44d933d537ea4fcc89747d25a5b0e647,
title = "Therapeutic potential of cannabidiol in depression",
abstract = "Major depressive disorder (MDD) is a widespread and debilitating condition affecting a significant portion of the global population. Traditional treatment for MDD has primarily involved drugs that increase brain monoamines by inhibiting their uptake or metabolism, which is the basis for the monoaminergic hypothesis of depression. However, these treatments are only partially effective, with many patients experiencing delayed responses, residual symptoms, or complete non-response, rendering the current view of the hypothesis as reductionist. Cannabidiol (CBD) has shown promising results in preclinical models and human studies. Its mechanism is not well-understood, but may involve monoamine and endocannabinoid signaling, control of neuroinflammation and enhanced neuroplasticity. This chapter will explore CBD's effects in preclinical and clinical studies, its molecular mechanisms, and its potential as a treatment for MDD.",
keywords = "Antidepressant, Glutamate, Monoamines, Neuroplasticity, Neurotransmitter, Stress",
author = "Guldager, \{Matti Bock\} and \{Chaves Filho\}, \{Adriano Maia\} and Caroline Biojone and S{\^a}mia Joca",
note = "Publisher Copyright: {\textcopyright} 2024",
year = "2024",
month = jan,
doi = "10.1016/bs.irn.2024.06.001",
language = "English",
isbn = "978-0-443-23591-7",
volume = "177",
series = "International Review of Neurobiology",
publisher = "Academic Press",
pages = "251--293",
booktitle = "Cannabidiol in Neurology and Psychiatry",
}